City of Hope and Adagene Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal Cancer
Key Highlights
- ➤Phase 1 trial will enroll up to 36 patients with advanced MSS colorectal cancer
- ➤Ivonescimab and ADG126 combination will assess safety, efficacy, and optimal dosing
- ➤City of Hope plans later combinations with 5-FU and irinotecan chemotherapy
- ➤Adagene says trial further validates ADG126 as a foundational combination backbone
- ➤Small 22-patient trial saw 82% response rate with ivonescimab and chemotherapy
Expert Statements
Marwan G. Fakih, Principal investigator, City of Hope professor and deputy director of City of Hope Comprehensive Cancer Center
“Colorectal cancer is the second deadliest cancer in the U.S., and current treatments don’t work for everyone. We urgently need to find new options, especially for the advanced stages of this challenging disease.”
Marwan G. Fakih, Principal investigator, City of Hope professor and deputy director of City of Hope Comprehensive Cancer Center
“Based on insights gleaned from past studies, we expect this powerful drug combination will result in more potent activation of the immune system within tumors, leading to potential tumor regression or death.”
Marwan G. Fakih, Principal investigator, City of Hope professor and deputy director of City of Hope Comprehensive Cancer Center
“Our mission is to speed lifesaving care to patients by crafting a more effective therapy that enhances quality of life and boosts survival rates.”
Marwan G. Fakih, Principal investigator, City of Hope professor and deputy director of City of Hope Comprehensive Cancer Center
“We hope that the combination of immunotherapy with ivonescimab and ADG126 will work hand in hand with chemotherapy to improve further tumor shrinkage in advanced colorectal cancer.”
Marwan G. Fakih, Principal investigator, City of Hope professor and deputy director of City of Hope Comprehensive Cancer Center
“The combination of ivonescimab, ADG126 and 5-FU has the potential to serve as a more effective maintenance therapy in metastatic colorectal cancer, deepening and maintaining responses to therapy. The combination of ivonescimab, ADG126, 5-FU and irinotecan has the potential to serve as a first-line treatment in metastatic colorectal cancer and improve further on the chances of remission, regression and duration of disease control.”
Peter Luo, Chairman, CEO and president of R&D at Adagene
“This is the third clinical program to combine muzastotug or ADG126 with a next generation PD-1 bispecific with the goal of driving additional survival benefit for patients. This trial further validates and broadens the potential use of ADG126 as a foundational combination backbone to potentially drive more clinically meaningful survival benefits for patients.”
Peter Luo, Chairman, CEO and president of R&D at Adagene
“ADG126 is designed to activate preferentially in the tumor microenvironment, enabling CTLA-4 blockade while limiting on-target, off-tumor activity in healthy tissues. By combining this approach with complementary immune, angiogenic and cytotoxic mechanisms, the study will assess the safety and preliminary antitumor activity of these regimens. We value City of Hope’s leadership and clinical expertise in colorectal cancer.”
Marwan G. Fakih, Principal investigator, City of Hope professor and deputy director of City of Hope Comprehensive Cancer Center
“The clock is ticking; we can’t afford to lose more patients to this devastating disease.”
Marwan G. Fakih, Principal investigator, City of Hope professor and deputy director of City of Hope Comprehensive Cancer Center
“Our study is a crucial step forward in finding better approaches for fighting advanced colorectal cancer.”
City of Hope and Adagene Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal Cancer
Study was designed by medical oncologist to accelerate lifesaving care to patients
Get started
Create a free account to read the full story.
